Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

NCT03661515 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT03661515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03661515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
Lead sponsor
PETHEMA Foundation
Phase
Phase 1
Overall status
Completed
Start date
July 17, 2018
Completion date
October 15, 2019
Enrollment
16 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia